What is RZLT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.47B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RZLT?

P/E (TTM) is n/a and 52-week range is $1.07 to $11.46 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RZLT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RZLT?

The company profile lists net income (TTM) near $-72M, EPS (TTM) near $-0.75 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Rezolute Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Redwood City, California, US, 96.3M shares outstanding, ISIN US76200L3096 when available from company profile and filing metadata.

Rezolute Inc

$RZLT

Health Care · Biotechnology

IR Run Scenarios

$4.87

+4.96%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 71 full-time employees. The company went IPO on 2011-12-23. Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.

Employees

Website

www.rezolutebio.com/

IPO

2011-12-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)